EMEA-001732-PIP02-15
Key facts
| Active substance |
Humanised chimeric antibody with a humanised H chain and a chimeric (mouse V-domain, human C-domain) L chain against epidermal growth factor receptor conjugated to maleimidocaproyl monomethylauristatin F (ABT-414)L chain against epidermal growth factor receptor conjugated to maleimidocaproylmonomethylauristatin F (ABT-414)
|
| Decision number |
P/0298/2016
|
| PIP number |
EMEA-001732-PIP02-15
|
| Pharmaceutical form(s) |
Powder for solution for injection or infusion
|
| Condition(s) / indication(s) |
Treatment of high-grade glioma
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
AbbVie Ltd
|
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|